In emerging therapy markets, traditional trial models often fall short. They are slow, expensive, and frequently exclude the very patients who stand to benefit most. Real-world evidence (RWE) fills this gap capturing lived experience in context to support smarter decision-making.

TrueMed’s RWE model offers sponsors three layers of strategic value:

1. Early Signal Validation
Before investing in full-scale trials, our consult-linked data and patient intake insights help sponsors assess real-world feasibility, interest, and suitability saving time and reducing risk.

2. Evidence for Market Access
Health payers, regulators, and prescribers increasingly demand patient-centred evidence. Our structured outputs support claims around quality of life, tolerability, and treatment acceptability.

3. Embedded Trust and Compliance
All data is collected via TGA-aligned consults and neutral tools. We do not endorse products or blur the line between marketing and medicine. This ensures long-term credibility and partnership value.

In short, RWE isn’t just data it’s a strategic asset. And TrueMed delivers it in a way that is faster, safer, and more aligned to emerging therapy realities than traditional models allow.

In emerging therapeutic markets, access to structured, high-quality real-world evidence (RWE) is critical. TrueMed helps sponsors capture patient-centred insights that inform feasibility, support regulatory compliance, and strengthen commercial positioning.

• Feasibility Study Design: Including draft protocols, participant pathways, and eligibility logic

• Data Collection: Through consults, trackers, intake tools, and ongoing patient engagement

• Patient & Prescriber Networks: For observational data and experience based insights

• Publication-Ready Outputs: Including feasibility reports, white papers, and policy briefs

• Study Frameworks: Adaptable for post-market surveillance, usage pattern mapping, or QoL trackin